IGXT Archives - Page 6 of 8

Developments

IntelGenx updates on cannabis-infused VersaFilm and RIZAPORT programs

IntelGenx (TSXV:IGX; OTCQX:IGXT) has finalized its cannabis-infused VersaFilm product with co-development partner, Tilray (NASDAQ:TLRY), and has completed manufacturing scale-up work. “Because we believe this is an...

January 13, 2020

Markets

Echelon starts IntelGenx at speculative buy; PT $1.60

Echelon Wealth Partners launched coverage of IntelGenx (TSXV:IGX; OTCQX:IGXT) with a “speculative buy” rating and price target of $1.60 (Canadian). The stock closed at 73 cents on Oct. 29. The firm’s flagship...

October 29, 2019

Developments

FDA accepts IntelGenx NDA resubmission for RIZAPORT

The FDA accepted IntelGenx’s (TSXV:IGX; OTCQX:IGXT) 505(b)(2) NDA resubmission for RIZAPORT VersaFilm for the treatment of acute migraines. The FDA also assigned a PDUFA goal date for completion of the NDA review of...

October 22, 2019

Developments

IntelGenx receives positive DSMB recommendation for Montelukast VersaFilm trial

IntelGenx (TSX-V:IGX; OTCQX:IGXT) reported that an independent data safety monitoring board (DSMB) completed its first interim analysis of the company’s ongoing Montelukast VersaFilm Phase 2a clinical trial, called...

October 9, 2019

Executive Moves

IntelGenx names André Godin to additional post of president

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT) appointed André Godin to the additional position of president. He continues as CFO and will continue to report to CEO, Dr. Horst Zerbe.

May 9, 2019

Developments

IntelGenx and Aquestive Therapeutics in global collaboration for Tadalafil

IntelGenx (TSXV:IGX; OTCQX:IGXT) entered into a definitive worldwide agreement with Aquestive Therapeutics (NASDAQ:AQST), a specialty pharmaceutical company, for the co-development and commercialization of Tadalafil...

May 8, 2019

Developments

IntelGenx receives second U.S. patent for oral film technology

IntelGenx (TSXV:IGX; OTCQX:IGXT) received its second patent from the U.S. Patent and Trademark Office, covering design and manufacturing of topical oral films for the local treatment of diseases of the oral mucosa using...

May 1, 2019

Developments

IntelGenx to demonstrate oral films CDMO services at CPhI North America

IntelGenx (TSXV:IGX; OTCQX:IGXT) plans to demonstrate the capabilities of its contract development and manufacturing organization (CDMO) services and its VersaFilm and VetaFilm oral film technologies, at CPhI North...

April 23, 2019

Developments

IntelGenx files U.S. patent application for oil-based active ingredients

IntelGenx (TSX-V:IGX; OTCQX:IGXT) filed a new non-provisional patent application with the U.S. Patent and Trademark Office, covering a newly developed platform that enables incorporation of oil-based (lipophilic) active...

April 16, 2019

Developments

IntelGenx receives positive feedback for Montelukast VersaFilm at ADPD conference

IntelGenx’s (TSX-V:IGX) (OTCQX:IGXT) Montelukast VersaFilm program received positive and constructive feedback from the scientific community at the 14thInternational Conference on Alzheimer’s & Parkinson’s Diseases...

April 8, 2019

Tag - IGXT

IntelGenx updates on cannabis-infused VersaFilm and RIZAPORT programs

Echelon starts IntelGenx at speculative buy; PT $1.60

FDA accepts IntelGenx NDA resubmission for RIZAPORT

IntelGenx receives positive DSMB recommendation for Montelukast VersaFilm trial

IntelGenx names André Godin to additional post of president

IntelGenx and Aquestive Therapeutics in global collaboration for Tadalafil

IntelGenx receives second U.S. patent for oral film technology

IntelGenx to demonstrate oral films CDMO services at CPhI North America

IntelGenx files U.S. patent application for oil-based active ingredients

IntelGenx receives positive feedback for Montelukast VersaFilm at ADPD conference

General

More